Clinical Trial Update: Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection [Phase 2]

View source ↗

Summary

Vir Biotechnology reports that the Phase 2 study of VIR-2218, VIR-3434, and PEG-IFNα for chronic hepatitis B infection has been completed. The release does not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• PEG-IFNα (pegylated interferon alfa)
• VIR-2218
• VIR-3434

Snippet

Sponsor: Vir Biotechnology, Inc. | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED